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Abstract 
Predicting Outcomes in Lost-to-follow-up Subjects from a 15-year Observational Study of 
Autosomal Dominant Polycystic Kidney Disease 
 
Anni Guo, MS 
 
University of Pittsburgh, 2020 
 
 
Abstract 
 
 
Autosomal dominant polycystic kidney disease (ADPKD) is a common chronic hereditary 
kidney disease, mainly characterized by kidney volume growth and cyst formation. Chronic 
Kidney Disease is the predictable result of ADPKD, which is usually defined as 5 stages (CKD, 
stage 1-5) from mild to severe by estimated Glomerular Filtration Rate (eGFR) values. 
The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) is 
a study of ADPKD patients’ kidney function decline. The participants were in different CKD 
stages and typically progress to worse CKD stages over time. CRISP was established, in large part, 
to describe the natural history of ADPKD. Given the necessary long-term follow-up, CRISP 
participants are often lost to follow-up (LTF).  
In order to better use data from the LTF participants, this study focuses on predicting the 
CKD status at for the LTF participants in CRISP and assessing whether there is a difference 
between the LTF participants and the non-LTF participants. To predict the trajectory of eGFR, 
participants were grouped based on the Mayo imaging classification (MIC), which uses age and 
height-adjusted total kidney volume (htTKV) to estimate the rate of htTKV growth. Within each 
MIC, a different mixed model was fit to predict eGFR trajectory; the final status of each LTF 
participant was then estimated based on that trajectory. Bootstrapping was used to assess the 
variability of the predictions. 
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Results described the predicted CKD status and showed a minimal impact of variability on 
the prediction, allowing us to effectively predict the final outcome of LTF ADPKD patients. 
Further, the predicted outcomes of the LTF participants were consistent with the observed outcome 
of the non-LTF participants, which indicated the group of LTF participants was a random subset 
of the entire cohort. 
The findings of the study are significant to public health. Because lack of follow-up will 
affect the effectiveness of the study, it is important to obtain the information of the LTF 
participants as much as possible. For ADPKD, an early understanding of the variability in patients 
with different disease risks could provide specific information for the development of disease, 
which is of great significance for proper prevention and treatment in the future. 
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1.0 Introduction 
1.1 Autosomal Dominant Polycystic Kidney Disease (ADPKD) 
Autosomal dominant polycystic kidney disease (ADPKD), is a type of hereditary kidney 
disease. As a common kidney disorder, ADPKD is estimated to have a diagnosed prevalence of 
1:2000 and incidence of 1:3000-1:8000 on a global scale. In the United States, there are about 
6000 new cases are diagnosed each year. The typical clinical manifestations of ADPKD are the 
increase in the size of the kidney and the formation of kidney cysts, which is also accompanied by 
many extrarenal complications, such as liver cysts, intracranial aneurysms, and Cardiac Valvular 
Disease (CVD). [1] Patients with ADPKD may experience the following symptoms: abdominal 
pain, haematuria, serious upper urinary tract infections (UTIs), kidney stones, and several other 
symptoms. Mild symptoms may interfere with the patient’s normal life, but severe illness may 
cause great pain to the patient.  
ADPKD is a type of genetic condition where patients have a genetic mutation that accerates 
kidney volume growth and cyst formation. However, ADPKD rarely causes clinical symptoms 
and adverse affect kidney function later in life, e.g. around 30 to 60 years of age. Some of the 
variability in kidney function relates to the specific ADPKD mutation, which are PKD1, PKD2, 
or there may be no mutation detected (NMD). PKD1 accounts for nearly 85% of mutations. 
Patients with a PKD1 mutation usually have a greater number of cysts and thus an early onset of 
decline in renal function and presence of clinical symptoms. [2] [3] The degree of renal decline is 
often quantified by the condition of chronic kidney disease (CKD), where the kidney’s rate of 
filtration drops below normal function. As kidney function continues to decline, the patient may 
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eventually reach End-Stage Kidney Disease (ESKD), where the kidneys fail to work and a 
transplant or dialysis is needed.  [1] 
ADPKD is one of the leading causes of ESKD; more than 50% of ADPKD patients 
eventually develop ESKD. Although there is no cure for ADPKD, but there are treatments for 
symptoms or diseases caused by this disease. Treatments include drugs to treat urinary tract 
infections or high blood pressure, and surgery to remove kidney stones.  
1.2 Chronic Kidney Disease (CKD) 
As described above, CKD is defined as a loss of kidney function over time (usually over 
decades). CKD is a predictable outcome for patients with the genetic condition of ADPKD . [4] 
[5] In addition to the symptoms associated with kidney function, CKD is associated with other 
clinical complications, including heart disease, high blood pressure, bone disease, and anemia. [4] 
[6] As described by the National Kidney Foundation (NKF), there are guidelines that divide CKD 
into five stages from mild to severe, in order to help physicians identify the levels of kidney 
disease. [7] [4] The stages of CKD are based on the estimated Glomerular Filtration Rate (eGFR) 
values. GFR is a commonly used measure of kidney function to quantify how well the kidneys 
filter blood. GFR can either be measured directly by iothalamate clearance or estimated using 
serum creatinine and certain personal characteristics. In our study, eGFR is calculated by the 
creatinine-based Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, using 
the information of a person's age, gender, height, weight, race and creatinine levels:  
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GFRCKD−EPI  =  141 × 𝑚𝑖𝑛(Scr/κ ,1)
𝛼  ×  𝑚𝑎𝑥(Scr/κ, 1)−1.209 × 0.993Age  ×
 1.018 [If Gender =  Female]  ×  1.159 [If Race =  Black]. 
In the above formula, Scr is serum creatinine, the values of κ and α are constants; κ = 0.7 
for females and κ = 0.9 for males; α = –0.329 for females and α = –0.411 for males, min indicates 
the minimum of Scr/κ or 1, and max indicates the maximum of Scr/κ or 1. [8] [9] 
Stages of CKD are displayed in Table 1 [10]: 
 
Table 1 CKD Stage Description 
Stage GFR (ml/min) Description % of kidney function 
1 ≥ 90 Normal functioning kidney >90% 
2 [60, 90] Mild decrease in kidney function 60%-90% 
3a [45, 60] Mild-moderate decrease in kidney function 45%-59% 
3b [30, 45] Moderate-severe decrease in kidney function 30%-44% 
4 [15, 30] Severe decrease in kidney function 15%-29% 
5 ≤ 15 Kidney failure-ESKD <15% 
 
CKD stage 1 represents completely normal kidney function and stage 5 represents a nearly 
complete loss of kidney function. CKD stages 3 (also sometimes broken into 3a and 3b.) is usually 
considered the cut-off for having CKD, as kidney function loss in stage begins to result in clinical 
symptoms. At stage 4, the individual has significant kidney damage. Development of CKD stage 
5 often requires a transplant or dialysis. [11] [12] In addition to presence of ADPKD, a number of 
factors can affect the rate of GFR decline over time. [13] 
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1.3 Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) 
The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) is 
an ongoing observational cohort study of 241 ADPKD participants that seeks to characterize the 
natural history of ADPKD and measure and evaluate biomarkers for prognosis of CKD and ESKD. 
For some of those biomarkers, characteristics of kidney structure and function are captured using 
high-resolution magnetic resonance (MR) imaging, including kidney volume, renal blood flow, 
and number and volume of cysts. [14] Data on baseline covariates (e.g. age, sex, and PKD 
mutation) was collected in 2001, and participants have been followed longitudinally with initially 
annually (through 3 follow-up visits over the first 5 years of the study) and then approximately bi-
annually (with 4 planned visits) for the subsequent 10 years.  
1.4 Motivation 
As a long-term cohort study, one of the main challenges in CRISP is obtaining complete 
data collection on subjects over the extended time of follow-up. Some of participants may 
withdraw from the study for various reasons. Reasons may be random, such as having moved away 
from the clinical site during the study, or non-random reasons, such as becoming too ill to continue. 
This means that we do not know the final result of the participants’ CKD development, so that 
these participants are considered to be lost to follow-up (LTF). Lost to follow-up is very important 
in determining a study's validity because LTF participants may tend to have a different prognosis 
than those who complete the study. 
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The CRISP data used for the current analysis was closed in 2016, after 15 years of follow-
up. The timepoint of a participant entered the cohort study will be defined as Year 0. We picked 
Year 12 as a cut-off point for lost to follow-up, because clinic visits are spread out during the 
study. So a participant that fully participates may still have their final visit a few years before Year 
15.  In contrast, if their last visit was before Year 12, we considered them LTF.  
For the purposes of the current study, we on whether the participant reached ESKD or CKD 
Stage 5 (subsequently referred to as stage 5), and whether the predicted outcome of LTF partipants 
differs from those who continued past Year 12. There were 44 subjects, who did not reach stage 5 
and did not have eGFR data past Year 12; they were defined as lost-to-follow-up (LTF). 
 
 
Figure 1 Definition of Lost to follow-up Participants 
(1). Do not have an eGFR measured after Year 12. (2) Without ESKD or CKD stage 5 during observation. 
 
CRISP investigators assume that LTF participants are essentially a random subset. For 
instance, some of the participants have to move because of family reasons or other "random" events 
that cause them to become LTF. The question is whether the group of LTF participants is similar 
to those with adequate follow-up or observed end point outcomes, or whether the LTF group is a 
biased subset that looks much worse than those still under study. If we see that the predicted 
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proportion of stage 5 is much higher in those LTF as compared to those with complete follow-up 
(greater than12 years or reach ESKD), this would indicate potential for a bias in who is LTF. In 
contrast, we may see the predicted proportion of 5 stage is much lower in the LTF since they 
necessarily exclude those with ESKD, and data capture of ESKD is generally considered to be 
near complete. 
For the purposes of this current study, our first step was to predict the eGFR values, and 
the corresponding predicted probability of reaching stage 5 at Year 15 for the LFT participants in 
CRISP. Second, we assessed the variability of the predicted eGFR values using bootstrapping. 
Predicted eGFR values and the predicted proportion reaching CKD stage 5 (which is a eGFR < 15 
mm/min) in the LTF participants were then compared to the observed results in those not LTF.  
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2.0 Methodology 
2.1 Description of Data Source 
The CRISP data set used for this analysis was closed in 2016, after 15 years of follow-up. 
After removing participants who were defined as ‘atypical’, there were 236 participants included 
in our study. 41 participants reached stage 5 and 39 participants had dialysis or kidney transplant. 
For the 156 remaining subjects, 112 had follow-up past year 12; the remaining 44 subjects were 
defined as lost-to-follow-up (LTF). Summary statistics are displayed for baseline variables to 
describe the two groups. 
2.2 Simple Linear Regression 
While linear regression is not directly used in this study, the basic method is presented as 
some background before introducing linear mixed models (which are used to predict eGFR at year 
15 for the LTF group). Simple linear regression estimates the average response for values of a 
given explanatory variable. Other subject characteristics, such as treatment or other demographic 
characteristics) could also be included in the estimation (which would be a multiple regression 
model). 
For 𝑖th observation 𝑥𝑖, 
𝑦𝑖 = 𝛽0 + 𝛽1𝑥𝑖 + 𝜀𝑖  
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In the above equation, 𝑦𝑖 is the measurement for the dependent random variable Y, 𝛽0 is 
the true intercept, 𝛽1 is slope, 𝑥𝑖 is the measurement for the independent random variable X, and 
𝜀𝑖 is the random error term which is assumed to be independently identically distributed (i.i.d.): 
𝜀𝑖~𝑁(0, 𝜎
2), and 𝑦𝑖~𝑁(𝛽0 + 𝛽1𝑥𝑖, 𝜎
2), i.i.d.. 
The method of ordinary least squares (OLS) is used to estimate the coefficients in the model 
with the estimator: 
?̂?1 =
∑ (𝑥𝑖 − ?̅?)(𝑦𝑖 − ?̅?)
𝑛
𝑖=1
∑ (𝑥𝑖 − ?̅?)2
𝑛
𝑖=1
 
 
?̂?0 = ?̅? − ?̂?1?̅? 
 
In the above equation, ?̅? is the sample mean of the independent variable, ?̅? is the sample 
mean of the dependent variables. 
As noted above, the simple (and multiple) linear regression model method assumes 
independent observations. However, CRISP data has longitudinal measurements of the key 
outcome of eGFR; for this scenario, observations are not independent, thus yielding invalid 
standard errors. In other words, for the longitudinal data in CRISP, we are measuring the same 
subject multiple times so that these observations on the same subject are correlated. If we ignore 
the dependence between the observations, estimation of covariate effects will be biased leading to 
incorrect inference. 
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2.3 Mixed Effect Model 
A longitudinal mixed model contains both a within-subjects factor (time-random factor) 
and a between-subjects factor (fixed factors). The mixed effects model for longitudinal data is 
given by: 
 
𝑦𝑖𝑗𝑘 = 𝜇 + 𝛼𝑗 + 𝛽𝑘 + 𝛼𝛽𝑗𝑘 + 𝜀𝑖𝑗𝑘 
 
𝜀𝑖𝑗𝑘~𝑁(0, 𝜎
2) 
 
The parameter μ is the overall average outcome (e.g. eGFR), for ith subject, jth level, and 
kth time point, 𝛼𝑗 is the fixed effect (usually the demographical variables), 𝛽𝑘 is the fixed effect of 
time (the time each measurement occurs), and 𝛼𝛽𝑗𝑘 is the time by fixed effect interactions. The 
error term 𝜀𝑖𝑗𝑘 can be estimated by a block diagonal covariance matrix R, in which each block 
corresponds to a different subject. The structure of the blocks in R reflects the researchers’ 
assumptions about the pattern of error correlations within subjects. [15] 
In previous studies of eGFR [11], the data were analyzed with polynomial mixed effect 
models with linear and quadratic terms of the covariate of age. Previous results of the CRISP study 
showed that the quadratic term of age in the mixed effects model was statistically significant; 
adding a quadratic term for age is also consistent with the underlying biology, where GFR may 
stay steady or increase in early life and then decrease sharply later in life. The polynomial mixed 
effect model that was subsequently established in the previous CRISP study is expressed as: 
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𝑦𝑖𝑗 = 𝛽0 + 𝛽1𝑥𝑖𝑗 + 𝛽2𝑥𝑖𝑗
2 + 𝜁0𝑗 + 𝜀𝑖𝑗 
 
In the above equation, 𝑦𝑖𝑗 is the eGFR value for subject j at time i, 𝑥𝑖𝑗 is age of subject j at 
time i, 𝑥𝑖𝑗
2  is quadratic term of age of child j at time i 𝜁0𝑗  is the specific intercept deviation of 
subject j, and 𝜀𝑖𝑗 is the random residual error.  
2.4 Mayo Classification 
CRISP and other studies have begun using a newly developed approach to categorize 
ADPKD patients based on their rate of height-adjusted TKV (htTKV) growth over time. Because 
htTKV growth is highly predictable over time [16], the rate of kidney growth can be reliably 
estimated by using a single htTKV measurement and the subject’s current age. Irazabel, et al. [17] 
suggested five subgroups (see Table 2) to characterize the subject’s rate of kidney growth referred 
to as the Mayo Classification. [17]  
 
Table 2 Mayo Classification Description 
Subgroup htTKV Growth Rate/Year (%) 
A <1.5% 
B 1.5%–3% 
C 3%–4.5% 
D 4.5%–6% 
E >6% 
 
Over the follow up period, most CRISP participants had 4-8 eGFR measurements. In past 
studies, based on plotting the eGFR trajectory over time, Yu et al. indicated that for ADPKD 
patients with different severity of CKD, the processes of loss of kidney function have different 
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trajectories. Patterns of GFR decline have been found to be significantly different in these five 
subgroups of the Mayo classification, all showing non-linear decline trajectories. [11] The 
participants with Mayo classification type A (slow kidney volume growth) tend to have normal 
ranges of eGFR, and will hardly reach CKD stage 5. Participants in categories B and C also tend 
to remain relatively normal, although some may drop to CKD stage 5 based on their initial eGFR. 
Class D and E participants (the group with the fastest kidney volume growth) tend to have very 
rapid renal failure in their 40s or 50s and reach CKD stage 5. 
Yu et al. [11] showed that if a separate mixed-effect polynomial model is fitted in each 
Mayo classification, we will obtain a well-fitting model for predicting eGFR decline. The studies 
have shown that, although there is substantially variable in GFR trajectories over time, the Mayo 
Classification can be used to predict whether subjects will likely reach CKD stage 5 over a given 
period of time. Therefore, we will use existing methods (including Mayo classification and mixed 
effect models, where age and age squares are used as predictors, which are also affected by the 
random intercept of each subject) based on all their data to obtain the predicted values of GFR for 
the 44 LFT patients after 15 years passed from the baseline time point that the patients entered the 
cohort study. 
Five mixed effect models were established for each Mayo classification with the formula: 
 
eGFR = 𝛽0 + 𝛽1 × Age + 𝛽2 × Age
2 
 
Where 𝛽0 is intercept, 𝛽1 is the coefficient of participants’ age (after 15 years passed from 
the baseline time point), and 𝛽2 is the coefficient of participants’ age
2 (age: after 15 years passed 
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from the baseline time point).  [11] [17] The models explained the relationship between increasing 
age and decreasing GFR values. 
 
Table 3 Coefficients for the Published Mixed Effect Regression Polynomial Model 
 CKD-EPI eGFR 
Class 𝛽0 𝛽1 𝛽2 
A 79.16 1.47 -0.03 
B 72.89 2.30 -0.05 
C 121.64 0.37 -0.04 
D 111.44 1.74 -0.07 
E 98.06 2.87 -0.11 
2.5 Bootstrap Method 
The Bootstrap method is a statistical resampling technique which is used to estimate the 
statistics of the population. The basic idea for Bootstrap is: for a sample of size n, we sample from 
the original data with replacement. The probability of each observation in the original data being 
drawn each time is 
1
𝑛
, and the new obtained samples are called Bootstrap samples. Then an 
estimated value 𝜃 of the parameter θ can be obtained for each bootstrap sample. 
Let random sample 𝑋 = {𝑥1, 𝑥2, … , 𝑥𝑛}  be independent and identically distributed 
samples, 𝑥𝑖~𝐹(𝑥), 𝑖 = 1, 2, … , 𝑛. 𝑅(𝑋, 𝐹) is a function of X and F. To estimate the distribution 
characteristics of 𝑅(𝑋, 𝐹) based on the observed samples 𝑋 = {𝑥1, 𝑥2, … , 𝑥𝑛}, we let 𝜃 = 𝜃(𝐹) 
be a parameter of the overall distribution F, 𝐹𝑛  is the empirical distribution function of the 
observation sample X, and 𝜃 = 𝜃(𝐹𝑛) is an estimate of θ, the estimation error is: 
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𝑅(𝑋, 𝐹) = 𝜃(𝐹𝑛) − 𝜃(𝐹) ≜  𝑇𝑛 
 
The basic steps for calculating the distribution characteristics of 𝑅(𝑋, 𝐹) are summarized 
as follows: 
1) Construct the empirical distribution function 𝐹𝑛  according to the observation sample 𝑋 =
{𝑥1, 𝑥2, … , 𝑥𝑛}; 
2) Take samples from 𝐹𝑛 called Bootstrap samples; 
3) Calculate the corresponding Bootstrap statistic 𝑅∗(𝑋∗, 𝐹𝑛), which can be expressed as: 
 
𝑅∗(𝑋∗, 𝐹𝑛) = 𝜃(𝐹𝑛
∗) − 𝜃(𝐹𝑛) ≜  𝑅𝑛 
 
Where 𝐹𝑛
∗  is the empirical distribution function of the Bootstrap sample; 𝑅𝑛  is the 
Bootstrap statistic of 𝑇𝑛; 
4) Repeat process 2) and 3) N times to get N possible values of Bootstrap statistic 𝑅∗(𝑋∗, 𝐹𝑛); 
5) Use the distribution of 𝑅∗(𝑋∗, 𝐹𝑛) to approximate the distribution of 𝑅(𝑋, 𝐹), that is, use the 
distribution of 𝑅𝑛  to approximate the distribution of 𝑇𝑛 , getting N possible values of the 
parameter 𝜃(𝐹).  
After these steps, we can estimate the distribution of the parameter θ. 
 
The confidence interval is a commonly used interval estimation method. The confidence 
level represents the frequency (ie, the ratio) of possible confidence intervals that contain the true 
values of unknown population parameter 𝜃(𝐹).  
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Confidence intervals provide a range of model properties. When predicting new data from 
the model, it shows the likelihood that the model ’s predictions will fall between these ranges. For 
the bootstrap method, we use a non-parametric method to obtain the 95% confidence interval of 
the bootstrap estimate statistics. This form of confidence interval does not make any assumptions 
about the functional form of the statistical distribution, which is often called an empirical 
confidence interval. [18] 
To obtain the 95% confidence interval, first, we sort the bootstrap estimated statistics, and 
then select the values at the selected percentile for the confidence interval. In this case, the selected 
percentile is called alpha. We take a 95% confidence interval in this study, and the alpha should 
be 0.95. We will choose a lower limit of 2.5% and an upper limit of 97.5% in the statistical data 
of interest. 
In this study, we calculated 1,000 bootstrap estimates of the eGFR values using the 
predicted eGFR at Year 15 from the mixed model corresponding that subject’s Mayo classification. 
A total of 1,000 bootstrap samples were used to assess variability of the prediction. More 
specifically, the 1,000 predictions for each subject were ordered and the bootstrap confidence 
interval was defined as the range from the lower limit of the 25th value (i.e. 2.5 percentile) to the 
upper limit of the 975th value (i.e. 97.5 percentile). The overall prediction estimate of eGFR for 
the given subject was defined as the mean prediction over all 1,000 bootstrap samples. A chi-
squared test was used to evaluate the difference in distributions between outcomes between the 
predictions in the LTF participants group versus the observed results in the non-LTF participants 
group. 
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3.0 Results 
3.1 Summarized Statistics 
Table 4 Baseline and Follow-up Information of CRISP Data 
Variables                           Mean (sd)/Numbers 
Baseline age 32.26 (± 8.80) 
Baseline height-adjusted total kidney volume (ml/m) 615.71 (± 371.32) 
Baseline estimated glomerular filtration rate (mm/min) 92.48 (±22.97) 
Mayo classification   
A 15 (6.36%) 
B 59 (25.00%) 
C 69 (29.24%) 
D 55 (23.30%) 
E 38 (16.10%) 
  
Last observed GFR value (mm/min)  65.98 (± 33.92) 
<12 years of follow-up 68.75 (± 21.29) 
>12 years of follow-up 65.37 (± 36.16) 
 
Table 4 shows the baseline demographics and follow-up information on key characteristics. 
The mean baseline age of the participants was 32 years old, with a mean baseline height-adjusted 
total kidney volume (htTKV) equal to 615.71 ml/m, and a mean baseline GFR equal to 92.48 
mm/min. There were 15 (6.36%) participants defined as Mayo classification subgroup A, 59 (25%) 
participants defined as subgroup B, 69 (29.24%) participants defined as subgroup C, 55 (23.3%) 
participants defined as subgroup D, and 38 (16.1%) participants defined as subgroup E. The 
participants with follow-up data past year 12 had a mean last observed GFR equal to 65.37 
mm/min, and participants with follow-up data did not past year 12 had a mean last observed GFR 
equal to 68.75 mm/min. 
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3.2 Predicted Results of Mixed Models 
Based on the bootstrap predicted eGFR, we classified the LTF participants’ status into 
different CKD stages according to Table 1.  
 
Table 5 Observed and Predicted Outcomes 
 Observed Outcomes Predicted Outcomes** 
Outcome Status Not lost to follow-up (%) 
N=192 
lost to follow-up (%) 
N=44 
lost to follow-up (%) 
N=44 
CKD Stage 1-4 112 (58.3%) 44 (100%) 37 (84.10%) 
CKD Stage 5 41 (21.35%) 0 7 (15.90%) 
Transplant or Dialysis 39 (20.31%) 0 N/A* 
*By definition, transplant and dialysis cases were not lost-to-follow-up (since follow-up ended with those 
endpoints).  
**Using the linear mixed model prediction stratified by Mayo classification.  
 
The observed CKD status as determined by the last eGFR measurement are shown in Table 
5 for the 192 non-LTF participants and the 44 LTF participants. For the non-LTF participants, 112 
out of 192 (58.3%) were distributed in CKD stage 1 to CKD stage 4, and 41 out of 192 (21.35%) 
were distributed in CKD stage 5, the remaining 39 (20.31%) participants had dialysis or had kidney 
transplants. By definition, participants that had transplant and dialysis were not lost-to-follow-up 
and placed into CKD stage 5. For all the 44 LTF participants, by the definition of lost to follow-
up, none of them were observed to reach stage 5 (which we defined above to also include transplant 
or dialysis). Table 5 also includes the predicted CKD status at Year 15 for the LTF participants. 
Thirty-three out of 44 (75%) of the LTF participants were predicted to enter CKD stage 1-4, and 
7 out of 44 (15.9%) of the LTF participants were predicted to entered CKD stage 5. 
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3.3 Comparison Between the LTF and non-LTF participants 
The first Chi-square test was performed to test whether there is a difference between the 
observed outcome of CKD status for the non-LTF group and the last observed outcome for LTF 
group. By definition, the participants who had transplant or dialysis were not lost-to-follow-up and 
we included these participants into the CKD stage 5 category in the non-LTF group. The test 
showed a highly significant difference in the distributions of CKD stage (p < 0.001).  
The second Chi-square test was performed to test whether there is a difference between the 
observed outcome of CKD status of the non-LTF group and the predicted outcome of CKD status 
of LTF group. This test also showed a highly significant statistically difference (p = 0.003). 
In the last Chi-square test, we excluded the participants with transplant or dialysis in the 
non-LTF group, leaving 41 participants in the stage 5 category in the non-LTF group. This test 
result did not show significant evidence of a difference (p = 0.20). 
3.4 Variability of the Prediction 
In order to assess the variability of the predicted results, we obtained the 95% confidence 
interval of the predicted eGFR values from the results of the 1000 bootstrap samples for each LTF 
participant.  
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Table 6 Bootstrap Estimated Confidence Intervals for Each LTF Participants 
PKDID 
Predicted 
eGFR results 
Estimated lower bound 
eGFR values (mm/min) 
Estimated upper bound 
eGFR values (mm/min) 
Confidence 
Interval Range 
101585 
110080 
124300 
126133 
139126 
139486 
151030 
157925 
159106 
160928 
161547 
170121 
174632 
193273 
194105 
195310 
223343 
223534 
229428 
234650 
236202 
244111 
256171 
268455 
271662 
273214 
281977 
285601 
293598 
300911 
40.69728381 
45.52781638 
-18.1575771 
53.10674238 
23.83644708 
58.52622913 
65.43612562 
47.11595925 
-17.22714702 
73.12228185 
43.49753274 
42.58607359 
48.48095831 
93.19847999 
49.18083686 
16.2052006 
42.183622 
41.6907207 
49.64102834 
70.46465327 
-1.46459333 
80.55609091 
57.64797842 
37.61255369 
35.01634132 
52.33923618 
46.83095289 
0.22227941 
6.602780805 
30.88226106 
32.80055409 
38.45119642 
-38.6993049 
47.06648205 
14.34498292 
53.19565422 
26.5172416 
32.87862303 
-34.9481604 
44.22419632 
27.70950077 
26.44361487 
40.74091753 
89.02268672 
42.67824522 
2.856998907 
34.4436392 
34.42244963 
43.14674492 
65.98054413 
-15.5315141 
76.56188008 
47.73398763 
28.21745705 
25.27802386 
46.2922519 
40.18076431 
-15.93869691 
-8.043853523 
20.60385737 
48.32806574 
52.5303288 
0.831825318 
59.10662857 
32.75847472 
64.02913262 
101.4835439 
60.41606549 
-1.33548771 
98.31974357 
58.13826684 
57.47134958 
56.47280187 
96.97687493 
55.78861069 
28.64369023 
49.69080254 
48.64874748 
56.16508073 
75.00315204 
11.55206201 
84.45187722 
67.17170105 
46.81119075 
44.23487087 
58.39118179 
53.3525621 
15.01838136 
20.25150795 
40.65371875 
15.527512 
14.079132 
39.53113 
12.040147 
18.413492 
10.833478 
74.966302 
27.537442 
33.612673 
54.095547 
30.428766 
31.027735 
15.731884 
7.954188 
13.110365 
25.786691 
15.247163 
14.226298 
13.018336 
9.022608 
27.083576 
7.889997 
19.437713 
18.593734 
18.956847 
12.09893 
13.171798 
30.957078 
28.295361 
20.049861 
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313307 
320182 
333524 
337315 
343097 
368973 
385151 
393936 
394588 
406726 
407648 
407841 
430543 
476972 
48.29998448 
41.84832159 
-60.5032608 
64.88506202 
23.27844031 
87.33682813 
46.38274098 
46.17002127 
3.700605099 
96.90678149 
43.38818101 
57.84644868 
40.07922576 
69.12819449 
34.56533314 
34.59907904 
-92.84873214 
60.01622656 
13.69960926 
83.82869707 
39.67887176 
39.460845 
-9.633219476 
92.89960229 
27.55672426 
48.01296056 
32.05261557 
62.81637155 
61.12978717 
48.77222102 
-30.73508699 
69.79544425 
32.26517626 
90.8624546 
52.92528579 
52.72241382 
15.90816275 
101.0256293 
58.05822761 
67.34093867 
47.74792584 
75.83287343 
26.564454 
14.173142 
62.113645 
9.779218 
18.565567 
7.033758 
13.246414 
13.261569 
25.541382 
8.126027 
30.501503 
19.327978 
15.69531 
13.016502 
 
Table 6 shows the mean of the bootstrap predicted eGFR values, lower bound and upper 
bounds of the 95% confidence interval of the predicted eGFR values at 15-year follow-up for each 
LTF participant, and the range of the 95% confidence interval (CI range). Because eGFR = 15 
mm/min was a cut-off point of the dichotomized results, CKD stage 1-4 and CKD stage 5, we were 
interested in the LTF participants who had a 95% confidence interval containing eGFR = 15 
mm/min. We could see that there were just a few of the participants (n=6) had a confidence interval 
that contained eGFR = 15 mm/min, highlighted in yellow. Thirty-eight out of the 44 LTF 
participants had a 95% confidence interval that did not contain GFR value = 15 mm/min. As eGFR 
value decreases by 30 mm/min, the CKD stage deteriorates by one level, we observed those 
participants whose confidence interval range exceeds 30 (n=9) and found that there were only one 
of them had the 95% confidence interval including eGFR = 15 mm/min, the others all had either 
confidence interval upper bound smaller than 15 or lower bound larger than 15, clearly classified 
to CKD stage 5 or CKD stage 1-4 
Table 6 Continued 
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Figure 2 Histogram of Bootstrap Predicted Results, pkdid=236202 
 
Figure 3 Histogram of Bootstrap Prediced Results, pkdid=195310 
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Figure 4 Histogram of Bootstrap Predicted Results, pkdid=244111 
 
Figure 2, 3 and 4 showed the histograms of the bootstrap predicted results of certain LTF 
participants. The x-axis represented the bootstrap predicted eGFR values (mm/min) at Year 15 and 
the y-axis showed the number of times the predicted GFR value fell into a certain range out of 
1000 bootstrap predictions. Also, eGFR = 15 mm/min was a cut-off point of the dichotomized 
results, CKD stage 1-4 and CKD stage 5. As shown in the figures, participant pkdid = 236202 had 
most of the predicted eGFR values smaller than 15 mm/min and only very few of the predicted 
results fell into the range of 10-20 mm/min, so that the participant was tent to be classified as CKD 
in stage 5. On the contrary, the participant pkdid = 244111 had all bootstrap predicted eGFR values 
larger than 15 mm/min, which indicated that the participants was tent to be classified as in CKD 
stage 1-4. Finally, the participant pkdid = 195310 had most of the bootstrap predicted eGFR values 
fell into range 10-20 mm/min, which showed that the predicted CKD stages of this participants 
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contain both CKD stage 1-4 and CKD stage 5. Overall, these results showed that, while there is 
some sampling variability reflected in the results in predictions, that variability was low enough to 
yield estimates that were relatively stable in terms of whether a given subject was or was not 
predicted to reach stage 5. 
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4.0 Discussion 
For the 44 LTF participants in the CRISP study, we used established mixed models, 
specific to a subject’s Mayo classification (i.e. their rate of kidney volume increases) to predict the 
eGFR at Year 15. Then, the predicted proportion reaching stage 5 was then compared with the 
observed outcomes of non-LTF participants to evaluate whether there were differences between 
the two participant groups. Bootstrapping was also used to assess sampling variability and 
calculate confidence intervals for the eGFR predictions.  
In previous studies, the Mayo classification was found to be an effective risk stratification 
tool that is the new standard in predicting kidney outcomes in high risk patients. However, the 
Mayo classification did not give the researchers the prediction specifically. Yu, et al., fitted 
separate mixed models within each Mayo classification to predict eGFR over a subject’s adult life 
as a function of age and age-squared, which indicated ADPKD patients with different Mayo 
classification had different prognosis trajectories of eGFR decline. In this study, we refitted the 
mixed models and applied them in predicting a specific ADPKD participant’s eGFR value based 
on a single observation of the age.  
The three Chi-square test results led to several conclusions. The result of Chi-square test 
for observed outcomes showed that the observed outcomes of CKD status were different between 
the LTF and non-LTF participants. Because the LTF participants all had their last observed eGFR 
before Year 12, we assumed that some of them may enter worse CKD stage as they age (or reach 
Year 15), so that the outcome of the CKD status of LTF group may become more similar to the 
non-LTF group. Therefore, we conducted another chi-squared test, including participants with 
transplant or dialysis in stage 5 and included in the non-LTF group. This test indicated that the 
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predicted outcome of CKD status of LTF participants were different from the observed outcome 
of CKD status of non-LTF participants. However, our data also showed that some of the non-LTF 
participants had kidney transplants or dialysis with their last observed eGFR values larger than 15 
mm/min. In other words, some of the participants may receive transplant or dialysis at an earlier 
time (in CKD stage 1-4) rather than after they entered CKD stage 5. Based on this scenario, it is 
reasonable to assume that such a situation may also occur among LTF participants. In this case, 
we did the third chi-squared test between the two groups. In order to eliminate the influence of this 
factor, we excluded the participants who had transplant and dialysis from the non-LTF group. The 
test result showed there was no significant evidence that the predicted outcome of CKD status of 
LTF participants were different from the observed outcome of CKD status of non-LTF 
participants. Therefore, we concluded that in this situation, the outcome of the CKD status at 
Year 15 of the LTF participants was consistent with the outcome of non-LTF participants, so that 
the LTF group was considered to be the random subset of the cohort in CRISP. 
The bootstrap confidence intervals provided estimates of the variability of the predicted 
results. For the 44 LTF participants, only six (13.6%) of them yielded confidence intervals 
containing eGFR = 15 mm/min. As shown in Figure 2, 3, and 4, only six participants who had 
confidence interval containing eGFR = 15 mm/min may had inconsistent predicted CKD status in 
the 1000 bootstrap samples. Therefore, this approach seemed to yield sufficiently precise estimates 
of which subjects would reach stage 5 to then compare to those who were not lost to follow-up. 
Overall, results seem relatively consistent with the hypothesis that LTF participants represent a 
random subset of the total data set, i.e. LTF participants were lost from the cohort because of 
mostly random events, rather than non-random events.  
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There were limitations to this study. First, the CRISP sample size had only a moderately 
large sample size. Other studies, including analysis of completed randomized trials, are ongoing 
at other sites with larger sample sizes. The data on eGFR was also irregularly spaced over different 
time periods, thus limiting precision of estimates at Year 15. There was also some error in defining 
who had completed the study, as the cut-off of Year 12 was relatively arbitrary. However, despite 
these limitations, the CRISP cohort provides a rather unique characterization of clinical 
characteristics and imaging measurements.  
It is meaningful for public health to understand the patterns of disease developments, and 
the same is true for the ADPKD patients. Because lack of follow-up will affect the effectiveness 
of the study, it is important to obtain the information of the LTF participants as much as possible. 
Early understanding of the variability in patients with different disease risks could provide specific 
information for the development of disease, which is of great significance for proper prevention 
and treatment in the future. 
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Appendix A Histograms of Bootstrap Estimated Results for Other LTF Participants 
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Appendix Figure 1 Histograms of Bootstrap estimated results for other LTF participants 
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Appendix B Code Used in R 
# Packages 
library(car) 
library(MASS) 
library(lme4) 
library(lmerTest) 
library(MuMIn) 
library(tidyr) 
library(readxl) 
library(ggplot2) 
 
#Data sets 
#"last egfr and IC from CRISP 3_with transplant and dialysis" is the data set contains the baseline info 
#"data_b is a sorted data set including the indicator of the first observation and the last observation of a 
participant 
 
data<-as.data.frame(read_excel("D:/Dr. Landsittel/CRISP/last egfr and IC from CRISP 3_with transplant 
and dialysis.xls")) 
data0<-as.data.frame(read_excel("D:/Dr. Landsittel/CRISP/data_b.xls")) 
data.ori<-as.data.frame(read_excel("D:/Dr. Landsittel/CRISP/CRISP I-III variables for Anni thesis.xls")) 
 
data.first<-subset(data0,n1==1) 
data.last<-subset(data0,n1==n2) 
 
data.final<-merge(data.last, data, by="pkdid") 
a<-data.final$ckd_epi 
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a<-as.numeric(a) 
 
a<-na.omit(a) 
mean(a) 
sd(a) 
 
data.o<-subset(data.ori,data.ori$vis==0) 
data.final.2<-merge(data.final, data.o, by="p 
kdid") 
 
#Baseline and follow_up infomation 
 
mean(data.final.2$httkv) 
sd(data.final.2$httkv) 
 
mean(data.final.2$ckd_epi.y) 
sd(data.final.2$ckd_epi.y) 
 
table(data.final$IC) 
table(data.final$class) 
table(data.final$transplant) 
table(data.final$dialysis) 
 
attach(data.final) 
data.final$status[visc < 12 & ckd_epi >= 15 & transplant == 0 & dialysis == 0] <- "lost to follow up"   
detach(data.final) 
 
data.lf<-subset(data.final, data.final$status == "lost to follow up") 
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length(data.lf$pkdid) 
 
attach(data.final) 
data.final$status2[ckd_epi >=90 & transplant == 0 & dialysis == 0] <- "CKD stage 1" # 
data.final$status2[visc < 12 & ckd_epi >=90 & transplant == 0 & dialysis == 0] <- "obs lost 1" # 
data.final$status2[ckd_epi >=60 & ckd_epi < 90 & transplant == 0 & dialysis == 0] <- "CKD stage 2"  # 
data.final$status2[visc < 12 & ckd_epi >=60 & ckd_epi < 90 & transplant == 0 & dialysis == 0] <- "obs lost 
2" 
data.final$status2[ckd_epi >=45 & ckd_epi < 60 & transplant == 0 & dialysis == 0] <- "CKD stage 3a" # 
data.final$status2[visc < 12 & ckd_epi >=45 & ckd_epi < 60 & transplant == 0 & dialysis == 0] <- "obs lost 
3a" # 
data.final$status2[ckd_epi >=30 & ckd_epi < 45 & transplant == 0 & dialysis == 0] <- "CKD stage 3b" # 
data.final$status2[visc < 12 & ckd_epi >=30 & ckd_epi < 45 & transplant == 0 & dialysis == 0] <- "obs lost 
3b" # 
data.final$status2[ckd_epi >=15 & ckd_epi < 30 & transplant == 0 & dialysis == 0] <- "CKD stage 4"  # 
data.final$status2[visc < 12 & ckd_epi >=15 & ckd_epi < 30 & transplant == 0 & dialysis == 0] <- "obs lost 
4"  # 
data.final$status2[ckd_epi < 15] <- "CKD stage 5"     
data.final$status2[transplant == 1] <- "Transplant"        
data.final$status2[dialysis == 1] <- "Dialysis"  
detach(data.final) 
 
as.data.frame(table(data.final$status2)) 
 
#follow up > 12 
nonltfdata<-subset(data.final,visc >=12) 
attach(nonltfdata) 
nonltfdata$status[ckd_epi >=90] <- "CKD stage 1"                   #32 
 35 
nonltfdata$status[ckd_epi >=60 & ckd_epi < 90] <- "CKD stage 2"  #48 
nonltfdata$status[ckd_epi >=45 & ckd_epi < 60] <- "CKD stage 3a" #17 
nonltfdata$status[ckd_epi >=30 & ckd_epi < 45] <- "CKD stage 3b" #17 
nonltfdata$status[ckd_epi >=15 & ckd_epi < 30] <- "CKD stage 4"  #19 
nonltfdata$status[ckd_epi < 15] <- "CKD stage 5"                   #15 
nonltfdata$status[transplant == 1] <- "transplant"                   
nonltfdata$status[dialysis == 1] <- "dialysis"                    
detach(nonltfdata) 
as.data.frame(table(nonltfdata$status)) 
 
length(nonltfdata$pkdid) 
 
daa<-subset(data.final,visc < 12) 
length(daa$pkdid) 
as.data.frame(table(daa$status2)) 
 
 
#lost to follow up 
attach(data.lf) 
data.lf$status[ckd_epi >=90] <- "CKD stage 1"                   #24 
data.lf$status[ckd_epi >=60 & ckd_epi < 90] <- "CKD stage 2"  #19 
data.lf$status[ckd_epi >=45 & ckd_epi < 60] <- "CKD stage 3a" #10 
data.lf$status[ckd_epi >=30 & ckd_epi < 45] <- "CKD stage 3b" #1 
data.lf$status[ckd_epi >=15 & ckd_epi < 30] <- "CKD stage 4"  #6 
data.lf$status[ckd_epi < 15] <- "CKD stage 5"                   #29 
data.lf$status[transplant == 1] <- "transplant"                   
data.lf$status[dialysis == 1] <- "dialysis"    
detach(data.lf) 
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as.data.frame(table(data.lf$status)) 
 
length(data.lf$pkdid) 
 
lfckd<-data.lf$ckd_epi 
lfckd<-as.numeric(nlfckd) 
lfckd<-na.omit(nlfckd) 
mean(lfckd) 
sd(lfckd) 
 
data.nlf<-as.data.frame(read_excel("D:/Dr. Landsittel/CRISP/nltf.xls")) 
data.nlf 
nlfckd<-data.nlf$ckd_epi 
nlfckd<-as.numeric(nlfckd) 
nlfckd<-na.omit(nlfckd) 
mean(nlfckd) 
sd(nlfckd) 
 
 
#Chi-square Test 
#1.not LTF (combine T+D with stage 5) vs last observed status in LTF 
chisq_data_1 <- data.frame(ckd_1_4 = c(112,80),  
                           ckd_1_5 = c(44,0)) 
 
chisq.test(chisq_data_1) 
 
#2.not LTF (combine T+D with stage 5) vs predicted outcome in LTF 
chisq_data_2 <- data.frame(ckd_1_4 = c(112,80),  
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                           ckd_1_5 = c(37,7)) 
 
chisq.test(chisq_data_2) 
 
#3.not LTF (do not combine T+D with stage 5) vs predicted outcome in LTF 
chisq_data_3 <- data.frame(ckd_1_4 = c(112,41),  
                           ckd_1_5 = c(37,7)) 
 
chisq.test(chisq_data_3) 
 
#Mixed models 
load("D:/Dr. Landsittel/CRISP/Data/data_Anni.RData") 
 
# polynomial model for class A 
CKD_epi1<-mydata1[mydata1$class==1,]$ckd_epi 
age1<-mydata1[mydata1$class==1,]$age 
pkdid1<-mydata1[mydata1$class==1,]$pkdid 
 
age1_2=age1^2 
CKD_epi1_p<- lmer(CKD_epi1 ~age1+age1_2+( 1|pkdid1)) 
summary(CKD_epi1_p) 
 
# polynomial model for class B 
CKD_epi2<-mydata1[mydata1$class==2,]$ckd_epi 
age2<-mydata1[mydata1$class==2,]$age 
pkdid2<-mydata1[mydata1$class==2,]$pkdid 
 
age2_2=age2^2 
 38 
CKD_epi2_p<- lmer(CKD_epi2 ~age2+age2_2+( 1|pkdid2)) 
summary(CKD_epi2_p) 
 
# polynomial model for class C 
CKD_epi3<-mydata1[mydata1$class==3,]$ckd_epi 
age3<-mydata1[mydata1$class==3,]$age 
pkdid3<-mydata1[mydata1$class==3,]$pkdid 
 
age3_2<-age3^2 
CKD_epi3_p<- lmer(CKD_epi3 ~age3+age3_2+( 1|pkdid3)) 
summary(CKD_epi3_p) 
 
# polynomial model for class D 
CKD_epi4<-mydata1[mydata1$class==4,]$ckd_epi 
age4<-mydata1[mydata1$class==4,]$age 
pkdid4<-mydata1[mydata1$class==4,]$pkdid 
 
age4_2<-age4^2 
CKD_epi4_p<- lmer(CKD_epi4 ~age4+age4_2+( 1|pkdid4)) 
summary(CKD_epi4_p) 
 
# polynomial model for class E 
CKD_epi5<-mydata1[mydata1$class==5,]$ckd_epi 
age5<-mydata1[mydata1$class==5,]$age 
pkdid5<-mydata1[mydata1$class==5,]$pkdid 
 
age5_2<-age5^2 
CKD_epi5_p<- lmer(CKD_epi5 ~age5+age5_2+( 1|pkdid5)) 
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summary(CKD_epi5_p) 
 
 
 
#coefficient for individuals 
ICa_coef<-coef(CKD_epi1_p)$pkdid 
ICb_coef<-coef(CKD_epi2_p)$pkdid 
ICc_coef<-coef(CKD_epi3_p)$pkdid 
ICd_coef<-coef(CKD_epi4_p)$pkdid 
ICe_coef<-coef(CKD_epi5_p)$pkdid 
 
data<-as.data.frame(read_excel("D:/Dr. Landsittel/CRISP/last egfr and IC from CRISP 3_with transplant 
and dialysis.xls")) 
data0<-as.data.frame(read_excel("D:/Dr. Landsittel/CRISP/data_b.xls")) 
 
data.first<-subset(data0,n1==1) 
data.last<-subset(data0,n1==n2) 
data.final<-merge(data.last, data, by="pkdid") 
 
attach(data.final) 
data.final$status[visc < 12 & ckd_epi >= 15 & transplant == 0 & dialysis == 0] <- "lost to follow up"   
detach(data.final) 
 
data.lf<-subset(data.final, data.final$status == "lost to follow up") 
length(data.lf$pkdid) 
 
data.a<-merge(data.lf, data.f.final, by="pkdid") 
data.a$ckd_epi<-as.numeric(data.a$ckd_epi) 
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data.f.final<-merge(data.first, data.lf, by="pkdid") 
#p$ckd_epi<-as.numeric(levels(p$ckd_epi)[p$ckd_epi]) 
data.f.final$ckd_epi.x<-as.numeric(data.f.final$ckd_epi.x) 
 
 
et<-data.f.final$baseline_age+15 
et2<-et^2 
 
data.lf<-cbind(data.lf,et) 
data.f.final<-merge(data.first, data.lf, by="pkdid") 
 
#"Ic_coef" is the sorted coefficients of the participants 
ic_coef<-as.data.frame(read_excel("D:/Dr. Landsittel/CRISP/coef.xls")) 
lf_coef<-subset(ic_coef,pkdid %in% data.a$pkdid) 
 
 
#"pp" is used to calculate the predicted values 
pp<-data.frame( 
  pkdid=data.a$pkdid, 
  baseline_age=data.a$baseline_age.x, 
  ckd_epi=as.numeric(data.a$ckd_epi), 
  IC=data.a$IC.y, 
  et=et, 
  et2=et2 
) 
pp<-merge(pp,lf_coef,by="pkdid") 
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predict<-pp$intercept + pp$age*pp$et + pp$age2*pp$et2 
 
#"p" is the data set contains the baseline info and predicted info 
p<-data.frame( 
  pkdid=pp$pkdid, 
  baseline_age=pp$baseline_age, 
  ckd_epi=as.numeric(pp$ckd_epi), 
  intercept=pp$intercept, 
  age=pp$age, 
  age2=pp$age2, 
  IC=pp$IC.x, 
  et=pp$et, 
  et2=pp$et2, 
  predict_result=predict 
) 
 
#Bootstrap ############################################ 
 
#p<-as.data.frame(read_excel("D:/Dr. Landsittel/CRISP/p.xls")) 
#p$ckd_epi<-as.numeric(levels(p$ckd_epi)[p$ckd_epi]) 
#p$ckd_epi<-as.numeric(p$ckd_epi) 
#str(p) 
 
 
data0<-as.data.frame(read_excel("D:/Dr. Landsittel/CRISP/data_b.xls")) 
age2<-(data0$age)^2 
data0<-cbind(data0,age2) 
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data.bs<-cbind(data0$pkdid, data0$ckd_epi, data0$age, data0$age2, data0$class) 
 
data.bs<-data.frame( 
  pkdid=data0$pkdid,  
  ckd_epi=data0$ckd_epi,  
  age=data0$age,  
  age2=data0$age2, 
  class=data0$class) 
data.bs$ckd_epi<-as.numeric(levels(data.bs$ckd_epi)[data.bs$ckd_epi]) 
str(data.bs) 
 
table(data.bs$class) 
 
LTF_data<-data.frame( 
  pkdid=p$pkdid, 
  et=p$et, 
  et2=p$et2, 
  IC=p$IC 
) 
 
s<-matrix() 
 
for(i in 1:236){ 
  s[i]<-subset(data.bs,pkdid==data.final[i,1]) 
} 
s[1] 
 
for(i in 1:236){ 
 43 
  s[[i]]<-subset(data.bs,pkdid==data.final[i,1]) 
} 
s[[1]] 
 
#Start Bootstrapping 
nboot <-1000  #number of bootstrap samples 
m<-matrix(0, 44, 1000) 
bootstrap.m<-matrix() 
unl.bs<-matrix() 
 
set.seed(04202020) 
 
for(i in 1:nboot){ 
  bootstrap.m[i]<-sample(s,size=236,replace=TRUE) 
} 
 
for(i in 1:nboot){ 
  bootstrap.m[[i]]<-sample(s,size=236,replace=TRUE) 
  unl.bs[i]<-unlist(bootstrap.m[i]) 
} 
  bootstrap1 <- matrix() 
  bootstrap1 <- as.data.frame(bootstrap.m[[1]][1]) 
  for (i in 2:236) { 
    x <- as.data.frame(bootstrap.m[[1]][i]) 
    bootstrap1 <- rbind(bootstrap1, x) 
  } 
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  #bs contains all the 1000 BS samples 
  bs <- list() 
  for(i in 1:nboot){ 
    boots <- as.data.frame((bootstrap.m[[i]][1])) 
    for(j in 2:236){ 
      x <- as.data.frame(bootstrap.m[[i]][j]) 
      boots <- rbind(boots, x) 
    } 
    bs[[i]] <- boots 
  } 
   
 
 
#To obtain the coefficients of the 5 mixed model refitted by the 1000 samples 
s1<-matrix() 
s2<-matrix() 
s3<-matrix() 
s4<-matrix() 
s5<-matrix() 
 
for(i in 1:nboot){ 
s1[i]<-subset(bs[[i]],bs[[i]]$class==1) 
s2[i]<-subset(bs[[i]],bs[[i]]$class==2) 
s3[i]<-subset(bs[[i]],bs[[i]]$class==3) 
s4[i]<-subset(bs[[i]],bs[[i]]$class==4) 
s5[i]<-subset(bs[[i]],bs[[i]]$class==5) 
  } 
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for(i in 1:nboot){ 
  s1[[i]]<-subset(bs[[i]],bs[[i]]$class==1) 
  s2[[i]]<-subset(bs[[i]],bs[[i]]$class==2) 
  s3[[i]]<-subset(bs[[i]],bs[[i]]$class==3) 
  s4[[i]]<-subset(bs[[i]],bs[[i]]$class==4) 
  s5[[i]]<-subset(bs[[i]],bs[[i]]$class==5) 
} 
 
 
 
#coef1-coef5 contains the coefficents of 1000 mixed models for each Mayo classification 
 
coef1<-data.frame() 
for(i in 1:nboot){ 
coef1<- rbind(coef1,coef(summary(lmer(ckd_epi ~age+age2+( 1|pkdid), data=s1[[i]])))[,1]) 
} 
 
coef2<-data.frame() 
for(i in 1:nboot){ 
  coef2<- rbind(coef2,coef(summary(lmer(ckd_epi ~age+age2+( 1|pkdid), data=s2[[i]])))[,1]) 
} 
 
coef3<-data.frame() 
for(i in 1:nboot){ 
  coef3<- rbind(coef3,coef(summary(lmer(ckd_epi ~age+age2+( 1|pkdid), data=s3[[i]])))[,1]) 
} 
 
coef4<-data.frame() 
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for(i in 1:nboot){ 
  coef4<- rbind(coef4,coef(summary(lmer(ckd_epi ~age+age2+( 1|pkdid), data=s4[[i]])))[,1]) 
} 
 
coef5<-data.frame() 
for(i in 1:nboot){ 
  coef5<- rbind(coef5,coef(summary(lmer(ckd_epi ~age+age2+( 1|pkdid), data=s5[[i]])))[,1]) 
} 
 
m1<-subset(LTF_data,LTF_data$IC=="A") 
m2<-subset(LTF_data,LTF_data$IC=="B") 
m3<-subset(LTF_data,LTF_data$IC=="C") 
m4<-subset(LTF_data,LTF_data$IC=="D") 
m5<-subset(LTF_data,LTF_data$IC=="E") 
 
 
#To obtain the BS estimated eGFR values for 44 LTF participants 
 
pre1<-c() 
d1<-matrix() 
for(i in 1:nboot){ 
  pre1[i]<-coef1[i,1]+ m1[1,2]*coef1[i,2] + m1[1,3]*coef1[i,3] 
  d1<-cbind(d1,pre1[i]) 
} 
d1<-as.vector(d1) 
d1<-sort(d1) 
 
pre2<-c() 
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d2<-matrix() 
for(i in 1:nboot){ 
  pre2[i]<-coef1[i,1]+ m1[2,2]*coef1[i,2] + m1[2,3]*coef1[i,3] 
  d2<-cbind(d2,pre2[i]) 
} 
d2<-as.vector(d2) 
d2<-sort(d2) 
 
pre3<-c() 
d3<-matrix() 
for(i in 1:nboot){ 
  pre3[i]<-coef2[i,1]+ m2[1,2]*coef2[i,2] + m2[1,3]*coef2[i,3] 
  d3<-cbind(d3,pre3[i]) 
} 
d3<-as.vector(d3) 
d3<-sort(d3) 
 
…… 
 
pre44<-c() 
d44<-matrix() 
for(i in 1:nboot){ 
  pre44[i]<-coef5[i,1]+ m5[8,2]*coef5[i,2] + m5[8,3]*coef5[i,3] 
  d44<-cbind(d44,pre44[i]) 
} 
d44<-as.vector(d44) 
d44<-sort(d44) 
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#To obtain the 95% confidence interval 
 
ci1<-c(d1[25],d1[975]) 
ci2<-c(d2[25],d2[975]) 
ci3<-c(d3[25],d3[975]) 
…… 
ci44<-c(d44[25],d44[975]) 
 
 
#95% confidence interval 
boot.ci<-rbind(ci1,ci2,ci3,ci4,ci5,ci6,ci7,ci8,ci9,ci10, 
               ci11,ci12,ci13,ci14,ci15,ci16,ci17,ci18,ci19,ci20, 
               ci21,ci22,ci23,ci24,ci25,ci26,ci27,ci28,ci29,ci30, 
               ci31,ci32,ci33,ci34,ci35,ci36,ci37,ci38,ci39,ci40, 
               ci41,ci42,ci43,ci44) 
 
p<-p[ 
  order( p$IC ), 
  ] 
p 
 
d<-rbind(d1,d2,d3,d4,d5,d6,d7,d8,d9,d10, 
         d11,d12,d13,d14,d15,d16,d17,d18,d19,d20, 
         d21,d22,d23,d24,d25,d26,d27,d28,d29,d30, 
         d31,d32,d33,d34,d35,d36,d37,d38,d39,d40, 
         d41,d42,d43,d44) 
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#To obtain the corresponding CKD stages 
c.t <- cut(d, breaks = c(-150, 15, 30, 45, 60, 90, 150))  
attr(c.t , 'levels') 
attr(c.t , 'class') 
ckd_stage<-ordered(c.t , labels = c('CKD 1', 'CKD 2', 'CKD 3a', 'CKD 3b', 'CKD 4', 'CKD 5'))  
ckd_stage<-(na.omit(ckd_stage)) 
ckd_stage 
#write.csv(ckd_stage,"D:/Dr. Landsittel/CRISP/ckd_stage.csv",row.names = FALSE) 
 
 
c1<-ckd_stage[1:1000] 
c2<-ckd_stage[1001:2000] 
c3<-ckd_stage[2001:3000] 
…… 
c44<-ckd_stage[43001:44000] 
 
 
t1<-table(c1) 
t2<-table(c2) 
t3<-table(c3) 
…… 
t44<-table(c44) 
 
 
 
ckd_dis<-as.data.frame(rbind(t1,t2,t3,t4,t5,t6,t7,t8,t9,t10, 
                             t11,t12,t13,t14,t15,t16,t17,t18,t19,t20, 
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                             t21,t22,t23,t24,t25,t26,t27,t28,t29,t30, 
                             t31,t32,t33,t34,t35,t36,t37,t38,t39,t40, 
                             t41,t42,t43,t44)) 
 
#To obtain the % of CKD stage for 1000 eGFR values 
ckd_per<-ckd_dis/1000*100 
ckd_per 
 
p<-p[ 
  order( p$IC ), 
  ] 
p 
 
p<-cbind(p,ckd_per) 
p 
str(p) 
 
 
d<-cbind(pkdid=p$pkdid, IC=p$IC, d) 
d<-as.data.frame(d) 
d 
 
 
p<-p[ 
  order( p$pkdid ), 
  ] 
p 
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p<-p[ 
  order( p$IC ), 
  ] 
p 
 
#Histograms of predicted eGFR values 
 
#Examples 
hist(d29,xlab="Predicted eGFR values",main=paste("pkdid=",p$pkdid[29]))#236202(1) 
hist(d17,xlab="Predicted eGFR values",main=paste("pkdid=",p$pkdid[17]))#195310(2) 
hist(d21,xlab="Predicted eGFR values",main=paste("pkdid=",p$pkdid[21]))#244111(3) 
 
 
#Appendix 
par(mfrow=c(2,2)) 
hist(d1,main=paste("pkdid=",p$pkdid[1])) 
hist(d2,main=paste("pkdid=",p$pkdid[2])) 
hist(d3,main=paste("pkdid=",p$pkdid[3])) 
hist(d4,main=paste("pkdid=",p$pkdid[4])) 
par(mfrow=c(1,1)) 
 
par(mfrow=c(2,2)) 
hist(d5,main=paste("pkdid=",p$pkdid[5])) 
hist(d6,main=paste("pkdid=",p$pkdid[6])) 
hist(d7,main=paste("pkdid=",p$pkdid[7])) 
hist(d8,main=paste("pkdid=",p$pkdid[8])) 
par(mfrow=c(1,1)) 
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par(mfrow=c(2,2)) 
hist(d9,main=paste("pkdid=",p$pkdid[9])) 
hist(d10,main=paste("pkdid=",p$pkdid[10])) 
hist(d11,main=paste("pkdid=",p$pkdid[11])) 
hist(d12,main=paste("pkdid=",p$pkdid[12])) 
par(mfrow=c(1,1)) 
 
par(mfrow=c(2,2)) 
hist(d13,main=paste("pkdid=",p$pkdid[13])) 
hist(d14,main=paste("pkdid=",p$pkdid[14])) 
hist(d15,main=paste("pkdid=",p$pkdid[15])) 
hist(d16,main=paste("pkdid=",p$pkdid[16])) 
par(mfrow=c(1,1)) 
 
 
par(mfrow=c(2,2)) 
hist(d18,main=paste("pkdid=",p$pkdid[18])) 
hist(d19,main=paste("pkdid=",p$pkdid[19])) 
hist(d20,main=paste("pkdid=",p$pkdid[20])) 
hist(d22,main=paste("pkdid=",p$pkdid[22])) 
par(mfrow=c(1,1)) 
 
 
par(mfrow=c(2,2)) 
hist(d23,main=paste("pkdid=",p$pkdid[23])) 
hist(d24,main=paste("pkdid=",p$pkdid[24])) 
hist(d25,main=paste("pkdid=",p$pkdid[25])) 
hist(d26,main=paste("pkdid=",p$pkdid[26])) 
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par(mfrow=c(1,1)) 
 
par(mfrow=c(2,2)) 
hist(d27,main=paste("pkdid=",p$pkdid[27])) 
hist(d28,main=paste("pkdid=",p$pkdid[28])) 
hist(d30,main=paste("pkdid=",p$pkdid[30])) 
hist(d31,main=paste("pkdid=",p$pkdid[31])) 
par(mfrow=c(1,1)) 
 
par(mfrow=c(2,2)) 
hist(d32,main=paste("pkdid=",p$pkdid[32])) 
hist(d33,main=paste("pkdid=",p$pkdid[33])) 
hist(d34,main=paste("pkdid=",p$pkdid[34])) 
hist(d35,main=paste("pkdid=",p$pkdid[35])) 
par(mfrow=c(1,1)) 
 
par(mfrow=c(2,2)) 
hist(d36,main=paste("pkdid=",p$pkdid[36])) 
hist(d37,main=paste("pkdid=",p$pkdid[37])) 
hist(d38,main=paste("pkdid=",p$pkdid[38])) 
hist(d39,main=paste("pkdid=",p$pkdid[39])) 
par(mfrow=c(1,1)) 
 
par(mfrow=c(2,2)) 
hist(d40,main=paste("pkdid=",p$pkdid[40])) 
hist(d41,main=paste("pkdid=",p$pkdid[41])) 
hist(d42,main=paste("pkdid=",p$pkdid[42])) 
hist(d43,main=paste("pkdid=",p$pkdid[43])) 
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par(mfrow=c(1,1)) 
 
 
par(mfrow=c(2,2)) 
hist(d44,main=paste("pkdid=",p$pkdid[44])) 
par(mfrow=c(1,1)) 
 
 
 
#To obtain the average values of the 1000 BS estimated results 
 
bm1<-mean(d1) 
bm2<-mean(d2) 
bm3<-mean(d3) 
…… 
bm44<-mean(d44) 
 
bs_mean<-c(bm1,bm2,bm3,bm4,bm5,bm6,bm7,bm8,bm9,bm10, 
           bm11,bm12,bm13,bm14,bm15,bm16,bm17,bm18,bm19,bm20, 
           bm21,bm22,bm23,bm24,bm25,bm26,bm27,bm28,bm29,bm30, 
           bm31,bm32,bm33,bm34,bm35,bm36,bm37,bm38,bm39,bm40, 
           bm41,bm42,bm43,bm44) 
bs_mean 
 
 
 
p<-p[ 
  order( p$IC ), 
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  ] 
p 
 
 
data.results<-p 
data.results<-cbind(data.results,bs_mean,boot.ci) 
 
attach(data.results) 
data.results$bs_mean_status[bs_mean >=90] <- "CKD stage 1"                   #24 
data.results$bs_mean_status[bs_mean >=60 & bs_mean < 90] <- "CKD stage 2"  #19 
data.results$bs_mean_status[bs_mean >=45 & bs_mean < 60] <- "CKD stage 3a" #10 
data.results$bs_mean_status[bs_mean >=30 & bs_mean < 45] <- "CKD stage 3b" #1 
data.results$bs_mean_status[bs_mean >=15 & bs_mean < 30] <- "CKD stage 4"  #6 
data.results$bs_mean_status[bs_mean < 15] <- "CKD stage 5"                   #29 
detach(data.results) 
cbind(data.results$predicted_status, data.results$bs_mean_status) 
 
############Data sorting part  
#data.results is the "p" data set with some more variables 
 
attach(data.results) 
data.results$lastobs_status[ckd_epi >=90] <- "CKD stage 1"                   #24 
data.results$lastobs_status[ckd_epi >=60 & ckd_epi < 90] <- "CKD stage 2"  #19 
data.results$lastobs_status[ckd_epi >=45 & ckd_epi < 60] <- "CKD stage 3a" #10 
data.results$lastobs_status[ckd_epi >=30 & ckd_epi < 45] <- "CKD stage 3b" #1 
data.results$lastobs_status[ckd_epi >=15 & ckd_epi < 30] <- "CKD stage 4"  #6 
data.results$lastobs_status[ckd_epi < 15] <- "CKD stage 5"                   #29 
detach(data.results) 
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attach(data.results) 
data.results$predicted_status[predict_result >=90] <- "CKD stage 1"                   #24 
data.results$predicted_status[predict_result >=60 & predict_result < 90] <- "CKD stage 2"  #19 
data.results$predicted_status[predict_result >=45 & predict_result < 60] <- "CKD stage 3a" #10 
data.results$predicted_status[predict_result >=30 & predict_result < 45] <- "CKD stage 3b" #1 
data.results$predicted_status[predict_result >=15 & predict_result < 30] <- "CKD stage 4"  #6 
data.results$predicted_status[predict_result < 15] <- "CKD stage 5"                   #29 
detach(data.results) 
 
data.results<-data.results[ 
  order( data.results$IC ), 
  ] 
 
data.results<-cbind(data.results,bs_mean) 
 
data.results<-data.results[ 
  order( data.results$pkdid ), 
  ] 
data.results 
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